Karyopharm Therapeutics (KPTI) Invested Capital (2016 - 2025)
Karyopharm Therapeutics' Invested Capital history spans 14 years, with the latest figure at -$271.9 million for Q4 2025.
- For Q4 2025, Invested Capital fell 46.18% year-over-year to -$271.9 million; the TTM value through Dec 2025 reached -$271.9 million, down 46.18%, while the annual FY2025 figure was -$271.9 million, 46.18% down from the prior year.
- Invested Capital reached -$271.9 million in Q4 2025 per KPTI's latest filing, down from -$256.8 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of -$16.7 million in Q4 2022 to a low of -$271.9 million in Q4 2025.
- Average Invested Capital over 5 years is -$132.6 million, with a median of -$129.1 million recorded in 2021.
- Peak YoY movement for Invested Capital: soared 79.09% in 2022, then plummeted 717.76% in 2023.
- A 5-year view of Invested Capital shows it stood at -$79.7 million in 2021, then skyrocketed by 79.09% to -$16.7 million in 2022, then crashed by 717.76% to -$136.2 million in 2023, then plummeted by 36.57% to -$186.0 million in 2024, then tumbled by 46.18% to -$271.9 million in 2025.
- Per Business Quant, the three most recent readings for KPTI's Invested Capital are -$271.9 million (Q4 2025), -$256.8 million (Q3 2025), and -$232.7 million (Q2 2025).